S. A. Belkov

S. A. Belkov

Auto-generated profile, based on publicly available information

S. A. Belkov

Scientific Centre for Expert Evaluation of Medicinal Products; I.V. Davydovsky City Clinical Hospital

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 March 2020 in Safety and Risk of Pharmacotherapy
Verified
Journal Article
Open access
PDF file
RKR. Ye. Kazakov
R. Ye. Kazakov
OCO. A. Checha
O. A. Checha
IMI. A. Mazerkina
I. A. Mazerkina
EDE. Yu. Demchenkova
E. Yu. Demchenkova
TAT. A. Aleksandrova
T. A. Aleksandrova
ОМО. В. Муслимова
О. В. Муслимова
Фармакогенетические подходы к повышению эффективности и безопасности применения статинов на примере аторвастатина

3 July 2022 in Safety and Risk of Pharmacotherapy
Verified
Journal Article
Open access
PDF file
APA. B. Prokofiev
A. B. Prokofiev
SBS. A. Belkov
S. A. Belkov
RKR. E. Kazakov
R. E. Kazakov
NBNadezhda Berdnikova
Nadezhda Berdnikova
TRTatiana Rodina
Tatiana Rodina
EDE. Yu. Demchenkova
E. Yu. Demchenkova
Vancomycin is prescribed to patients in serious condition with infections caused by Gram-positive microorganisms; however, if the therapeutic plasma concentration of the medicinal product is exceeded, it can have a nephrotoxic effect.The aim of the study was to demonstrate the possibility of using therapeutic drug monitoring (TDM) to reduce the risk of developing nephropathy in intensive care unit patients with sepsis.Materials and methods: the study comprised a retrospective analysis of four clinical cases of patients with sepsis admitted to intensive care units of I.V. Davydovsky City Clinical Hospital in 2021 and treated with vancomycin. TDM of vancomycin plasma levels was performed by reverse-phase high-performance liquid chromatography with mass spectrometric detection.Results: using the four cases of septic patients, the study demonstrated that vancomycin at adequate case-specific doses may result in plasma concentrations beyond the therapeutic range. TDM of vancomycin concentrations helped to prevent further deterioration of renal dysfunction in one septic patient having developed acute kidney injury and to control the achievement of therapeutic vancomycin concentrations or timely adjust the dose to that effect in the other three cases.Conclusions: a timely correction of vancomycin dosing with plasma TDM allows for achieving high antimicrobial efficacy in patients with sepsis and minimising the nephrotoxic effect of the medicinal product. Studies of the feasibility of using TDM as a treatment personalisation tool for patients in serious condition will continue in the future.